Vaccentis names Martin Munte as CEO and strengthens board

12 July 2022

Swiss clinical-stage biotech Vaccentis, which is developing patient-specific medicines, today announced the appointment of Martin Munte, a veteran leader in biotech and pharma, with extensive executive experience from Amgen, (Nasdaq: AMGN) AstraZeneca (LSE: AZN) and Roche (ROG: SIX), as its new chief executive.

Martin Munte held a series of senior roles at Amgen for 12 years, most recently as external access engagement lead Europe. He previously held management positions at both AstraZeneca and Roche. He has strong expertise as a leader in general management, sales and marketing, policy, access, regulatory and business development.

The appointment further strengthens Vaccentis’ leadership team, following the appointment of three high-profile entrepreneurs, Matthias Oertle, Marcel Frei and Subhasis Roy, as members of a five-person board of directors in May, with Matthias Oertle serving as chairman.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK